These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 37196353)
21. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home. Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937 [TBL] [Abstract][Full Text] [Related]
22. Outpatient Randomized Crossover Comparison of Zone Model Predictive Control Automated Insulin Delivery with Weekly Data Driven Adaptation Versus Sensor-Augmented Pump: Results from the International Diabetes Closed-Loop Trial 4. Pinsker JE; Dassau E; Deshpande S; Raghinaru D; Buckingham BA; Kudva YC; Laffel LM; Levy CJ; Church MM; Desrochers H; Ekhlaspour L; Kaur RJ; Levister C; Shi D; Lum JW; Kollman C; Doyle FJ; Diabetes Technol Ther; 2022 Sep; 24(9):635-642. PubMed ID: 35549708 [No Abstract] [Full Text] [Related]
23. Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial. Isganaitis E; Raghinaru D; Ambler-Osborn L; Pinsker JE; Buckingham BA; Wadwa RP; Ekhlaspour L; Kudva YC; Levy CJ; Forlenza GP; Beck RW; Kollman C; Lum JW; Brown SA; Laffel LM; Diabetes Technol Ther; 2021 May; 23(5):342-349. PubMed ID: 33216667 [No Abstract] [Full Text] [Related]
24. Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial. O'Malley G; Messer LH; Levy CJ; Pinsker JE; Forlenza GP; Isganaitis E; Kudva YC; Ekhlaspour L; Raghinaru D; Lum J; Brown SA; Diabetes Technol Ther; 2021 Apr; 23(4):245-252. PubMed ID: 33155824 [No Abstract] [Full Text] [Related]
25. Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy. Davis GM; Peters AL; Bode BW; Carlson AL; Dumais B; Vienneau TE; Huyett LM; Ly TT Diabetes Care; 2023 Apr; 46(4):742-750. PubMed ID: 36787903 [TBL] [Abstract][Full Text] [Related]
26. Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop Trial. Ekhlaspour L; Raghinaru D; Forlenza GP; Isganaitis E; Kudva YC; Lam DW; Levister C; O'Malley G; Church MM; Lum JW; Buckingham B; Brown SA J Diabetes Sci Technol; 2023 Jul; 17(4):935-942. PubMed ID: 35473359 [TBL] [Abstract][Full Text] [Related]
27. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Bergenstal RM; Nimri R; Beck RW; Criego A; Laffel L; Schatz D; Battelino T; Danne T; Weinzimer SA; Sibayan J; Johnson ML; Bailey RJ; Calhoun P; Carlson A; Isganaitis E; Bello R; Albanese-O'Neill A; Dovc K; Biester T; Weyman K; Hood K; Phillip M; Lancet; 2021 Jan; 397(10270):208-219. PubMed ID: 33453783 [TBL] [Abstract][Full Text] [Related]
28. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial. McAuley SA; Trawley S; Vogrin S; Ward GM; Fourlanos S; Grills CA; Lee MH; Alipoor AM; O'Neal DN; O'Regan NA; Sundararajan V; Colman PG; MacIsaac RJ Diabetes Care; 2022 Feb; 45(2):381-390. PubMed ID: 34844995 [TBL] [Abstract][Full Text] [Related]
29. Hybrid Closed-Loop Control Is Safe and Effective for People with Type 1 Diabetes Who Are at Moderate to High Risk for Hypoglycemia. Anderson SM; Buckingham BA; Breton MD; Robic JL; Barnett CL; Wakeman CA; Oliveri MC; Brown SA; Ly TT; Clinton PK; Hsu LJ; Kingman RS; Norlander LM; Loebner SE; Reuschel-DiVirglio S; Kovatchev BP Diabetes Technol Ther; 2019 Jun; 21(6):356-363. PubMed ID: 31095423 [No Abstract] [Full Text] [Related]
30. Adaptability of Closed Loop During Labor, Delivery, and Postpartum: A Secondary Analysis of Data from Two Randomized Crossover Trials in Type 1 Diabetes Pregnancy. Stewart ZA; Yamamoto JM; Wilinska ME; Hartnell S; Farrington C; Hovorka R; Murphy HR Diabetes Technol Ther; 2018 Jul; 20(7):501-505. PubMed ID: 29958022 [TBL] [Abstract][Full Text] [Related]
31. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Kovatchev BP; Renard E; Cobelli C; Zisser HC; Keith-Hynes P; Anderson SM; Brown SA; Chernavvsky DR; Breton MD; Mize LB; Farret A; Place J; Bruttomesso D; Del Favero S; Boscari F; Galasso S; Avogaro A; Magni L; Di Palma F; Toffanin C; Messori M; Dassau E; Doyle FJ Diabetes Care; 2014 Jul; 37(7):1789-96. PubMed ID: 24929429 [TBL] [Abstract][Full Text] [Related]
32. Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions. Sherr JL; Buckingham BA; Forlenza GP; Galderisi A; Ekhlaspour L; Wadwa RP; Carria L; Hsu L; Berget C; Peyser TA; Lee JB; O'Connor J; Dumais B; Huyett LM; Layne JE; Ly TT Diabetes Technol Ther; 2020 Mar; 22(3):174-184. PubMed ID: 31596130 [No Abstract] [Full Text] [Related]
33. Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses. Nimri R; Grosman B; Roy A; Nir J; Fisch Shvalb N; Kurtz N; Loewenthal N; Gillon-Keren M; Muller I; Atlas E; Phillip M Diabetes Technol Ther; 2021 Apr; 23(4):268-276. PubMed ID: 33185480 [No Abstract] [Full Text] [Related]
34. Application of Zone Model Predictive Control Artificial Pancreas During Extended Use of Infusion Set and Sensor: A Randomized Crossover-Controlled Home-Use Trial. Forlenza GP; Deshpande S; Ly TT; Howsmon DP; Cameron F; Baysal N; Mauritzen E; Marcal T; Towers L; Bequette BW; Huyett LM; Pinsker JE; Gondhalekar R; Doyle FJ; Maahs DM; Buckingham BA; Dassau E Diabetes Care; 2017 Aug; 40(8):1096-1102. PubMed ID: 28584075 [TBL] [Abstract][Full Text] [Related]
35. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Garg SK; Weinzimer SA; Tamborlane WV; Buckingham BA; Bode BW; Bailey TS; Brazg RL; Ilany J; Slover RH; Anderson SM; Bergenstal RM; Grosman B; Roy A; Cordero TL; Shin J; Lee SW; Kaufman FR Diabetes Technol Ther; 2017 Mar; 19(3):155-163. PubMed ID: 28134564 [TBL] [Abstract][Full Text] [Related]
36. Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes. Forlenza GP; Buckingham BA; Christiansen MP; Wadwa RP; Peyser TA; Lee JB; O'Connor J; Dassau E; Huyett LM; Layne JE; Ly TT Diabetes Technol Ther; 2019 May; 21(5):265-272. PubMed ID: 30925077 [No Abstract] [Full Text] [Related]
37. Beneficial effects of automated insulin delivery over one-year follow-up in real life for youths and adults with type 1 diabetes irrespective of patient characteristics. Henry Z; Villar Fimbel S; Bendelac N; Perge K; Thivolet C Diabetes Obes Metab; 2024 Feb; 26(2):557-566. PubMed ID: 37905353 [TBL] [Abstract][Full Text] [Related]
39. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: preliminary studies in Padova and Montpellier. Bruttomesso D; Farret A; Costa S; Marescotti MC; Vettore M; Avogaro A; Tiengo A; Dalla Man C; Place J; Facchinetti A; Guerra S; Magni L; De Nicolao G; Cobelli C; Renard E; Maran A J Diabetes Sci Technol; 2009 Sep; 3(5):1014-21. PubMed ID: 20144414 [TBL] [Abstract][Full Text] [Related]
40. Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial. Tauschmann M; Allen JM; Wilinska ME; Thabit H; Acerini CL; Dunger DB; Hovorka R Diabetes Care; 2016 Nov; 39(11):2019-2025. PubMed ID: 27612500 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]